Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
ZIMMER BIOMET HOLDINGS, INC.
Last earnings -10.6% on 2026-04-28
Revenue grew 7.2% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
ZIMMER BIOMET HOLDINGS, INC. shows $8.23B in FY2025 revenue (+7.2% YoY), a 8.6% net margin, and 5.6% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001136869, latest 10-Q filed 2026-05-01) · EODHD · rules-based read · as of 6/17/2026, 7:30:57 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B |
| Gross profit | — | — | — | — | — |
| Operating income | $860M | $696M | $1.28B | $1.29B | $1.10B |
| Net income | $402M | $231M | $1.02B | $904M | $705M |
| Diluted EPS | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
| Net margin | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
58 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Last 90 days: 0 open-market buys · 2 sales
| 2026-05-29 | Yi Sang Group President, Asia Pacific | Sell | 4.20K @ $82.64 | $347K |
| 2026-05-29 | Yi Sang Group President, Asia Pacific | Sell | 800.00 @ $82.66 | $66.1K |